Effects of Compassion Meditation on Psychological Status in Patients With Diabetes: A Pilot Randomized Controlled Trial.

West J Nurs ResJun 29, 2026 (epub)
Clinical ResearchEndocrinologyOpen access

Seongkum Heo, Tammy Barbé, Justus Randolph et al.

✦ AI-curated · Sources linked

In 30 seconds

This pilot randomized controlled trial evaluated the effects of a 4-week compassion meditation intervention on psychological factors in patients with type 1 or type 2 diabetes. The study found that participants in the intervention group reported higher diabetes self-efficacy and lower diabetes distress at the 4-week follow-up compared to the control group.

Key findings

  • Intervention group showed higher diabetes self-efficacy at follow-up compared to control group.
  • Diabetes distress was significantly lower in the intervention group after 4 weeks.
  • Self-compassion improved in the intervention group, while self-esteem decreased in the control group.

Why it matters

Psychological distress is common in diabetes patients and can hinder self-management. Effective interventions like compassion meditation may improve psychological well-being, potentially leading to better diabetes management and outcomes.

Source

PubMed · PMID 42370575Free full text on PubMed Central

Published in West J Nurs Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.